Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Treatment for Advanced Colorectal Cancer.

Clinical trial NCT07343791 · RECRUITING

Trial details

NCT number: NCT07343791
Sponsor: JIANG LONGWEI
Status: RECRUITING
Phase: Early Phase 1
Study type: INTERVENTIONAL

DC-CIK Treatment Regorafenib Colorectal Cancer Immune Combination Therapy Iparomlimab and Tuvonralimab Injection

Start date: 2025-11-19
Primary completion: 2027-11-30
Enrollment: 14

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.